Print
Category: Immigration Matters Immigration Matters
Published: 25 July 2017 25 July 2017

When the scope of the Pharmaceutical Industries influence over congress, and, congress continually focusing on Doctors and Pharmacies as the primary cause of the opioid overdose epidemic to the near complete refusal to recognize border insecurity and transnational crime as the source of heroin and fentanyl that are killing people in large numbers, the motives of the orchestrated focus on the medical delivery profession then becomes increasingly suspect.

The lightly shielded truth, highlighted below, is that the lawful drug Opana is being illegally converted to an injectable. What the highlighted section means is people are obtaining the legal drug Opana and illegally converting it to an injectable. This focusing on the Prescription Drug and not the crime will continue to lead us nowhere if we are truly acting to curb overdose deaths.

Financially, who would benefit or what pharmaceutical entity would benefit when Opana leaves the market? Or, is significant money for influence involved?

Stranger things have happened. Follow the money. None of this narrative against doctors and pharmacists will curb the illegal drug use of heroin and fentanyl.

Remember, "Never let a crisis go to waste." Healthcare is over 20% of the U.S. economy. There is more than one way to milk a cow. It's always about money and power.

https://www.wsj.com/articles/u-s-asks-endo-to-pull-opana-er-painkiller-from-market-1496956321 

Endo says shipments of oxymorphone hydrochloride ER will end September 1
Wall Street Journal (07/21/17) Lombardo, Cara

Shipments of oxymorphone hydrochloride extended release (Opana ER) will end on September 1, Endo International announced Friday. According to a company spokeswoman, shipments will continue through that date to "enable time for patients currently taking Opana ER to work with their physicians to convert to an appropriate alternative treatment." She said the company's third-party manufacturer ended production of the drug in connection with Endo's recent announcement that it would pull the drug from store shelves. The spokeswoman stressed, "It is important to note that there is no recall." FDA last month asked Endo to stop selling the drug. The agency linked a 2012 reformulation of the drug to injection drug use and a 2015 outbreak of HIV and hepatitis C in Indiana. Also on Friday, Endo said that it will close plants in Huntsville, AL, where it makes generic opioids and eliminate 875 jobs.


Zack Taylor, Chairman
NAFBPO.org